Eight Years of Real-Life Experience with Smoothened Inhibitors in a Swiss Tertiary Skin Referral Center

SIMPLE SUMMARY: Vismodegib and sonidegib are targeted therapies inhibiting the hedgehog pathway, a key driver in the pathogenesis of basal cell carcinoma (BCC). Hedgehog inhibitors (HhIs) are first-line therapy for locally advanced basal cell carcinoma (laBCC), metastatic basal cell carcinoma (mBCC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Grossmann, Lara E., Ramelyte, Egle, Nägeli, Mirjam C., Dummer, Reinhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139771/
https://www.ncbi.nlm.nih.gov/pubmed/35626100
http://dx.doi.org/10.3390/cancers14102496

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139771/
https://www.ncbi.nlm.nih.gov/pubmed/35626100
http://dx.doi.org/10.3390/cancers14102496

Ejemplares similares